Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Journal of Bone and Mineral Research

Volumn 26, Issue 5, 2011, Pages 1002-1011

  Frost, Michelle L ^a   Siddique, Musib ^a   Blake, Glen M ^a,d   Moore, Amelia Eb ^a   Schleyer, Paul J ^b   Dunn, Joel T ^b   Somer, Edward J ^b   Marsden, Paul K ^b   Eastell, Richard ^c   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

18F FLUORIDE; BONE FORMATION; OSTEOPOROSIS; POSITRON EMISSION TOMOGRAPHY; TERIPARATIDE

Indexed keywords

CALCIUM; FLUORINE 18; GE DISCOVERY PET/CT SCANNER; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG UPTAKE; FEMALE; FEMUR SHAFT; HUMAN; LUMBAR SPINE; OSSIFICATION; PELVIS; POSITRON EMISSION TOMOGRAPHY; TRABECULAR BONE;

AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; DEMOGRAPHY; FEMALE; FLUORIDES; FLUORINE RADIOISOTOPES; HUMANS; MIDDLE AGED; OSTEOGENESIS; POSITRON-EMISSION TOMOGRAPHY; STATISTICS, NONPARAMETRIC; TERIPARATIDE;

EID: 79955579900     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.305     Document Type: Article

References (40)

1. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990; 322: 1265-1271. (Pubitemid 20152489)
2. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348: 1535-1541. (Pubitemid 26411651)
3. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282: 637-645. (Pubitemid 29384151)
4. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999; 282: 1344-1352. (Pubitemid 29483192)
5. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med. 2001; 344: 1434-1441. (Pubitemid 32402100)
6. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19: 1241-1249. (Pubitemid 41094364)
7. Black DM, Delmas PD, Eastell R, et al. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-1822. (Pubitemid 46698462)
8. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-765.
9. Garnero P, Weichung JS, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79: 1693-1700.
10. Greenspan SL, Bone HG, Ettinger MD, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomzed trial. Ann Intern Med. 2007; 146: 326-339. (Pubitemid 351650593)
11. Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009; 45: 1053-1058.
12. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165: 1762-1768. (Pubitemid 41138965)
13. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16: 1846-1853. (Pubitemid 32911491)
14. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932-1941. (Pubitemid 37377441)
15. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005; 20: 1244-1253. (Pubitemid 40863814)
16. Lindsay R, Zhou H, Cosman F, et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22: 495-502. (Pubitemid 47457425)
17. Blake GM, Park-Holohan S, Cook GJR, Fogelman I., Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31: 28-49. (Pubitemid 32060651)
18. Hawkings RA, Choi Y, Huang S-C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992; 33: 633-642.
19. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997; 38: 1970-1976. (Pubitemid 28030932)
20. Cook GJ, Lodge MA, Marsden PK, et al. Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. Eur J Nucl Med. 1999; 26: 1424-1429. (Pubitemid 29515603)
21. 18F-fluoride positron emission tomography. J Bone Miner Res. 2003; 18: 2215-2222. (Pubitemid 37463315)
22. Installe J, Nzeusseu A, Bol A, et al. 18F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med. 2005; 46: 1650-1658. (Pubitemid 46211589)
23. Frost ML, Blake GM, Park-Holohan SJ, et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med. 2008; 49: 700-707. (Pubitemid 351717533)
24. 18F-fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endo Metab. 1993; 77: 949-955. (Pubitemid 23301469)
25. 18F-fluoride PET: correlation with bone histomorphometry. J Nucl Med. 2001; 42: 1091-1100. (Pubitemid 32595310)
26. Brenner W, Bohuslavizki KH, Sieweke N, et al. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997; 24: 1284-1290. (Pubitemid 27477622)
27. Uchida K, Nakajima H, Miyazaki T, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a propective study. J Nucl Med. 2009; 50: 1808-1814.
28. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005; 16: 510-516.
29. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: technical report series 843. Geneva: WHO, 1994.
30. Patel R, Blake GM, Rymer J, et al. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int. 2000; 11: 68-75. (Pubitemid 30099513)
31. Looker AC, Wahner HW, Dunn WL, et al. Proximal femur bone mineral levels of US adults. Osteoporos Int. 1995; 5: 389-409.
32. Park E, Cho M, Ki C-S., Correct use of repeated measures analysis of variance. Korean J Lab Med. 2009; 29: 1-9.
33. Blake GM, Frost ML, Fogelman I., Quantitative radionuclide studies of bone. J Nucl Med. 2009; 50: 1747-1750.
34. Moore AE, Blake GM, Taylor KA, et al. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res. 2010; 25: 960-967.
35. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350: 550-555. (Pubitemid 27348431)
36. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349: 1207-1215. (Pubitemid 37152030)
37. Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006; 91: 1370-1375.
38. Cann CE, Roe EB, Sanchez SD, Arnaud CD., PTH effects in the femur: envelope specific responses by 3DQCT in postmenopausal women. J Bone Miner Res. 1999; 14: S137 (abstract).
39. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18: 539-543. (Pubitemid 36241071)
40. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005; 36: 948-958. (Pubitemid 40797995)